Skip to main content

Table 2 Composition of CV9202

From: Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

Name

Gene symbol (other names)

mRNA length

New York esophageal squamous cell carcinoma 1

NY-ESO-1

760 bases

(CTAG1B)

Melanoma antigen family C 1

MAGEC1

1813 bases

(CT7)

Melanoma antigen family C 2

MAGEC2

1339 bases

(CT10/HCA587)

Baculoviral IAP repeat-containing 5

BIRC5

646 bases

(survivin/API4)

Trophoblast glycoprotein

TPBG

1480 bases

(5 T4/5 T4-AG/M6P1)

Mucin 1, cell surface associated

MUC1

1885 bases

(PEM)

  1. API4, apoptosis inhibitor 4; CT7/10, Cancer/testis antigen 7/10; CTAG1b, cancer/testis antigen 1B; HCA587, Hepatocellular Cancer Antigen 587; PEM, polymorphic epithelial mucin.